Biosymetrics, Inc.

BioSymetrics uses artificial intelligence and in vivo validation to identify drug targets and develop precision medicines by connecting disease phenotype and genotype data across human and model systems. The company focuses on target discovery programs in neurological, cardiometabolic, and rare diseases, including a lead program in epilepsy that leverages machine learning analysis of biological data from patient records and genomic profiles.